Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06697496 · ClinicalTrials.gov registry record · NA
A Smartphone Application (QuitBot) for the Improvement of Smoking Cessation Among American Indians and Alaska Natives, NAITIVE Trial
A NA study, sponsored by Fred Hutchinson Cancer Center.
- Not yet
- Registry status
- NA
- Development phase
- 772
- Enrollment target
NCT06697496: Clinical Trial NA study, sponsored by Fred Hutchinson Cancer Center.
NCT06697496 is a NA study that has not yet begun recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 772 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06697496, a NA study, has not yet begun recruiting, sponsored by Fred Hutchinson Cancer Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 772 participants
- Enrollment target
Study Summary
This clinical trial develops a chatbot smartphone application (app), QuitBot, and text messaging to help American Indians (AI) and Alaska Natives (AN) to quit smoking commercial tobacco (smoking cessation), and evaluates two remote smoking cessation programs to see how well they work for helping AI/AN people quit smoking commercial tobacco. AI/AN populations have one of the highest rates of commercial cigarette smoking of any racial and ethnic group in the United States (US). They also have a higher rate of developing smoking-related cancer but are less likely to quit smoking. The two programs are designed to provide personalized support in setting a smoking cessation goal, tasks to reach the smoking cessation goal, and motivation to remain smoke-free. This may help to keep participants engaged and support them in their quit efforts, and may improve smoking cessation among AI and AN.
Primary Outcome
Will use a logistic regression model and standard smoking cessation trial intent-to-treat analysis, with all missing outcomes will be coded as smoking. The model will adjust for stratification factors and baseline factors that are significantly related to the outcome. Sensitivity analyses will include: (1) multiple imputation of missing outcomes, (2) complete case analysis, and (3) carbon monoxide (CO)-verified results adjusted for use of other combustible nicotine-containing tobacco products at
Interventions
- OTHER Survey Administration
- OTHER Interview
- PROCEDURE Carbon Monoxide Measurement
- DEVICE QuitBot Smoking Cessation Chatbot Program
- DEVICE QuitBot Smoking Cessation Text Messaging Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 772 participants |
| Start Date | 2026-09-30 |
| Est. Completion | 2030-10-31 |
| Phase | NA |
What is known before NCT06697496 opens enrollment
NCT06697496 is an interventional study that assigns participants to a tested intervention. The registered 772 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 5 interventions - of which Survey Administration is the first listed.
NCT06697496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06697496 about?
NCT06697496 is a clinical study titled "A Smartphone Application (QuitBot) for the Improvement of Smoking Cessation Among American Indians and Alaska Natives, NAITIVE Trial". This clinical trial develops a chatbot smartphone application (app), QuitBot, and text messaging to help American Indians (AI) and Alaska Natives (AN) to quit smoking commercial tobacco (smoking cessation), and evaluates two remote smoking cessation programs to see how well they work for helping AI/...
What is the current status of trial NCT06697496?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 772 participants. The study started on 2026-09-30. Estimated completion is 2030-10-31.
What interventions are being tested in trial NCT06697496?
The interventions under investigation include: Survey Administration (OTHER), Interview (OTHER), Carbon Monoxide Measurement (PROCEDURE), QuitBot Smoking Cessation Chatbot Program (DEVICE), QuitBot Smoking Cessation Text Messaging Program (DEVICE).
Who is sponsoring clinical trial NCT06697496?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06697496's enrollment target sits among peer trials
772 143rd of 2000 higher than 1,858 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05977348 · 770 participants · NA
Increasing Food Literacy in Preschoolers to Reduce Obesity Risk
- NCT06376994 · 770 participants · Phase 3
Multi-Center Clean Air Randomized Controlled Trial in COPD
- NCT06824467 · 770 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- NCT06907173 · 770 participants · Phase 3
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI